Guerbet SA (EPA:GBT)

Market Cap	114.80M -58.9%
Revenue (ttm)	798.67M -6.2%
Net Income	-108.33M
EPS	-8.59
Shares Out	12.62M
PE Ratio	n/a
Forward PE	5.23
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,327
Open	8.72
Previous Close	8.73
Day's Range	8.72 - 9.10
52-Week Range	8.01 - 23.55
Beta	1.00
Analysts	Sell
Price Target	11.60 (+27.47%)
Earnings Date	Sep 15, 2026

About Guerbet

Guerbet SA provides a range of contrast media, medical devices, and digital and AI solutions for diagnostic and interventional imaging worldwide. It offers DOTAREM, a macrocyclic gadolinium-based contrast agent for use in contrast-enhanced MRI examinations; Elucirem, a macrocyclic gadolinium-based contrast agent for use in contrast-enhanced resonance imaging; UNIK, a diagnostic imaging interconnected solution; and Artirem, a gadoteric acid. The company also provides OptiStar Elite, a dual head contrast delivery system with an ultrasonic motor; ...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1901
• Employees: 2,746
• Stock Exchange: Euronext Paris
• Ticker Symbol: GBT

Analyst Summary

According to 3 analysts, the average rating for GBT stock is "Sell." The 12-month stock price target is €11.60, which is an increase of 27.47% from the latest price.

Price Target

€11.60

(27.47% upside)

Analyst Consensus: Sell

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 13, 2026

Data Sources Report a data error